
Philippe Aftimos/LinkedIn
Jun 3, 2025, 18:29
Philippe Aftimos Highlights ASCO 2025 Presentation by Elisa Agostinetto on SYNERGY Phase 2 Trial in Metastatic TNBC
Philippe Aftimos, Medical Oncologist at the Jules Bordet Institute, shared a post on LinkedIn:
“At the metastatic breast cancer poster session this morning at ASCO25, Elisa Agostinetto presents OS results and ctDNA analyses from the SYNERGY randomized phase 2 academic study sponsored by Institut Jules Bordet.
SYNERGY investigated the combination of oleclumab and durvalumab with chemotherapy in the 1st line setting of metastatic TNBC.”
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
Highlights from ASCO 2025 Day 3
Highlights from ASCO 2025 Day 4
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 17:02
Jun 4, 2025, 16:33
Jun 4, 2025, 16:33
Jun 4, 2025, 15:56
Jun 4, 2025, 14:21
Jun 4, 2025, 13:42